{
    "root": "f0a63075-631d-43bf-9d8e-df79faf0a278",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Levothyroxine Sodium",
    "value": "20250201",
    "ingredients": [
        {
            "name": "LEVOTHYROXINE SODIUM",
            "code": "9J765S329G",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00451"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "SODIUM BICARBONATE",
            "code": "8MDF5V39QO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01390"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        }
    ],
    "indications": {
        "text": "hypothyroidism levothyroxine sodium tablets indicated adult pediatric patients , including neonates , replacement therapy primary ( thyroidal ) , secondary ( pituitary ) , tertiary ( hypothalamic ) congenital acquired hypothyroidism . pituitary thyrotropin ( thyroid-stimulating hormone , tsh ) suppression levothyroxine sodium tablets indicated adult pediatric patients , including neonates , adjunct surgery radioiodine therapy management thyrotropin-dependent well-differentiated thyroid cancer . limitations \u2022 levothyroxine sodium tablets indicated suppression benign thyroid nodules nontoxic diffuse goiter iodine-sufficient patients benefits overtreatment levothyroxine sodium tablets may induce hyperthyroidism [ ( 5.1 ) ] . \u2022levothyroxine sodium tablets indicated treatment hypothyroidism recovery phase subacute thyroiditis .",
        "doid_entities": [
            {
                "text": "hypothyroidism (DOID:1459)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1459"
            },
            {
                "text": "thyroid cancer (DOID:1781)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1781"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            },
            {
                "text": "goiter (DOID:12176)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12176"
            },
            {
                "text": "hyperthyroidism (DOID:7998)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7998"
            },
            {
                "text": "subacute thyroiditis (DOID:7165)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7165"
            },
            {
                "text": "thyroiditis (DOID:7166)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7166"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 administer daily , preferably empty stomach , one-half one hour breakfast . ( 2.1 ) \u2022 administer least 4 hours drugs known interfere absorption . ( 2.1 ) \u2022 evaluate need dose adjustments regularly administering within one hour certain foods may affect absorption . ( 2.1 ) \u2022 advise patients stop biotin biotin-containing supplements least 2 days assessing tsh and/or t4 levels . ( 2.2 ) \u2022 starting dose depends variety factors , including age , body weight , cardiovascular status , concomitant medications . peak therapeutic effect may attained 4 6 weeks . ( 2.2 ) \u2022 full prescribing information dosing patient . ( 2.3 ) \u2022 adequacy therapy determined periodic monitoring tsh and/or t4 well status . ( 2.4 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "supplied levothyroxine sodium tablets usp round , colored , scored debossed following debossing details one side break-line side . supplied follows : strength ( mcg ) color/shape debossing details ndc # bottles 90 150 blue/round l24 82804-190-30 storage handling store 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0 f ) [ usp controlled room temperature ] . levothyroxine sodium tablets usp protected light moisture .",
    "adverseReactions": "levothyroxine sodium tablets contraindicated patients uncorrected adrenal insufficiency [ ( 5.4 ) ] .",
    "indications_original": "Hypothyroidism\n                  \n                  Levothyroxine sodium tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.\n                  \n                     Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression\n                  \n                  Levothyroxine sodium tablets are indicated in adult and pediatric patients, including neonates, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.\n                  \n                     Limitations of Use\n                  \n                  \n                     \n                        \u2022\n                        Levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism [see Warnings and Precautions (5.1)].\n                     \n                     \n                        \u2022Levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.",
    "contraindications_original": "\u2022 Administer once daily, preferably on an empty stomach, one-half to one hour before breakfast. ( 2.1 ) \u2022 Administer at least 4 hours before or after drugs that are known to interfere with absorption. ( 2.1 ) \u2022 Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect absorption. ( 2.1 ) \u2022 Advise patients to stop biotin and biotin-containing supplements at least 2 days before assessing TSH and/or T4 levels. ( 2.2 ) \u2022 Starting dose depends on a variety of factors, including age, body weight, cardiovascular status, and concomitant medications. Peak therapeutic effect may not be attained for 4 to 6 weeks. ( 2.2 ) \u2022 See full prescribing information for dosing in specific patient populations. ( 2.3 ) \u2022 Adequacy of therapy determined with periodic monitoring of TSH and/or T4 as well as clinical status. ( 2.4 )",
    "warningsAndPrecautions_original": "How Supplied\n                  \n                  Levothyroxine sodium tablets USP are round, colored, scored and debossed with following debossing details on one side and break-line on other side. They are supplied as follows:\n                  \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                  Strength (mcg)\n                                 \n                              \n                           \n                           \n                              \n                                  Color/Shape\n                                 \n                              \n                           \n                           \n                              \n                                  Debossing Details\n                                 \n                              \n                           \n                           \n                              \n                                  NDC# for bottles of 90\n                                 \n                              \n                           \n                        \n                        \n                           \n                               150\n                              \n                           \n                           \n                               Blue/Round\n                              \n                           \n                           \n                               L24\n                              \n                           \n                           \n                               82804-190-30\n                              \n                           \n                        \n                     \n                  \n                  \n                     Storage and Handling\n                  \n                  Store at 25\u00b0C (77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0 F) [see USP Controlled Room Temperature]. Levothyroxine sodium tablets USP should be protected from light and moisture.",
    "adverseReactions_original": "Levothyroxine sodium tablets are contraindicated in patients with uncorrected adrenal insufficiency [see Warnings and Precautions (5.4)].",
    "drug": [
        {
            "name": "Levothyroxine Sodium",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00451"
        }
    ]
}